A randomized controlled phase III adjuvant trial of high-dose bolus IL-2 [interleukin-2] in patients with high-risk renal cell carcinoma
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Interleukin-2 (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 04 Jan 2017 Biomarkers information updated
- 17 Sep 2005 New trial record.